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Abstract
Polypharmacy implies a high potential for drug-drug interactions. The capacity of the cytochrome P450 enzyme 
system involved in the metabolism of psychoactive drugs differs greatly, which leads to variable drug elimination rates 
and inter-subject differences in serum drug concentrations. Polymorphisms in genes coding for CYP450 enzymes 
contribute to this inter-subject variability. Therapeutic response and adverse effects vary among patients treated with 
the same dose of a certain drug. Polypharmacy, comorbidity and the use of certain substances (grapefruit juice, 
caffeine and tobacco) increase the chances of clinically relevant interactions in a psychotic patient. Choosing drugs 
with low interaction potential seems to be the best strategy to prevent clinically relevant interactions particularly in 
elderly, polymedicated, oncologic and HIV patients.
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Introduction
Drug-drug interactions (DDIs) are very common in clinical practice 
and are responsible for substantial increase in patient’s morbidity 
and mortality. Globally drug-drug interactions are responsible for 
approximately 20% to 30% of notified adverse reactions [1,2]. It has 
been estimated that the risk for drug-drug interactions increases 
substantially to about 84% when the number of concomitants drugs 
rise from 2 to 6 agents [1]. In addition, it is known that there is a great 
variability between individuals, and therefore, drug-drug interactions 
are not always easy to recognize [3,4].
Drug concentration at the site of action is regulated by absorption, 
distribution, metabolism, and excretion. Therefore, all these processes 
are keys to the pharmacologic action as well as the therapeutic efficacy 
and safety. A drug with unfavorable pharmacokinetic properties may 
result in an inadequate or inconsistent response, which may put the 
therapeutic use at risk. In addition, pharmacokinetics of a drug is 
usually a key factor for the appearance or absence of toxic effects, and 
as a result, it has a direct impact on the safety of treatment [5].
Drug-drug interactions resulting from absorption, distribution, 
metabolism, or elimination, as well as pharmacodynamic factors, 
are present for many common psychoactive medications. DDIs 
can negatively impact patient outcomes and can also have serious 
implications on the cost and quality of treatment. DDIs may be the 
cause of adverse drug reactions (ADRs) that put at risk the outcomes of 
therapy and the adherence to treatment [6,7].
The potential for DDIs is particularly increased in the elderly due 
to polytherapy. In fact, polypharmacy increases the complexity of 
therapeutic management, and therefore, the risk of clinically relevant 
DDIs, which can both induce the development of ADRs or reduce the 
clinical efficacy. The challenge presented by adverse DDIs in clinical 
psychiatry will continue to expand as the complexity of medication 
regimens increase in a population that receive more sophisticated 
and diverse psychotropic agents [8,9]. Most individuals with 
schizophrenia take medications indefinitely and at some point take 
additional medications. Therefore, the risk of polypharmacy-related 
complications is real in this population as well as the risk of reduced 
adherence to treatment [6,7].
The aim of the present article is to review and update common 
drug-drug interactions and its implications in the clinical use of 
antipsychotic drugs with a special focus on interactions associated to 
CYP450 enzymes (CYP’s) activity.
Drug-drug interactions
The two main types of DDIs are pharmacodynamic and 
pharmacokinetic interactions.
Pharmacodynamic interactions: In a pharmacodynamics 
interaction, two drugs have synergistic or antagonistic effects, without 
changes in their pharmacokinetic profile. There are many examples of 
pharmacodynamic interactions with antipsychotics.
Thus, some antipsychotics with anticholinergic properties, as 
clozapine, chlorpromazine and trifluoperazine, can cause constipation. 
The association of these agents with opioids, for example codeine, 
increased the constipation. Furthermore, the synergistic anticholinergic 
effect of drugs, such as antiparkinsonian agents, can increase the 
anticholinergic effects of these antipsychotics, leading to dry mouth, 
blurred vision, and possibly delirium [10].
Potential pharmacodynamic interactions can be present with 
addition of many other drugs to antipsychotics. This includes all sedative 
drugs, as benzodiazepines, antihistaminics, some antidepressants, 
increasing the risk of sedation. On the other hand, pro-convulsant 
drugs added to atypical antipsychotics, especially clozapine and 
olanzapine can increase the risk of seizures [11,12].
Many antihypertensives in association with antipsychotic drugs 
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may increase the risk of falls and postural hypotension. Furthermore, 
a pharmacodynamic drug interaction may be the result of combining 
two or more drugs with established risk of prolongation of corrected 
QT interval (QTc), such as chlorpromazine and haloperidol [11,13]. 
The association of haloperidol with amiodarone or ondansetron can 
also induce a prolongation of QTc interval [14].
On other occasions, the association of an antipsychotic with 
other drugs can have an antagonistic effect, leading to treatment 
failure and a risk of relapse. An example of this may occur when 
combining antipsychotics with dopaminergic drugs for Parkinsonism, 
e.g., levodopa or dopaminergic receptors agonists. The result may be 
worsening motor function, a relapse of psychosis or a combination of 
both [10].
Pharmacokinetic interactions: Pharmacokinetic interactions 
may occur through various mechanisms, including alterations in drug 
absorption, distribution, metabolism, and excretion. The alteration 
of any of these processes may be associated with treatment failure or 
toxicity. Pharmacokinetic DDIs are usually identified by controlling 
the patient’s clinical symptoms as well as the changes in serum drug 
concentrations.
For example, quetiapine pharmacokinetics is affected by 
concomitant administration of ketoconazole and carbamazepine, 
drugs that strongly modulate the activity of CYP3A4. Another example 
are the pharmacokinetic interactions between smoking and drugs that 
are CYP1A2 substrates, such as clozapine, and olanzapine [15,16].
Typically, pharmacodynamic DDIs can be anticipated by drug’s 
mechanism of action and receptor occupancies, and these interactions 
can often be predicted and prevented. However, pharmacokinetic DDIs 
are much more difficult to anticipate. Knowing how a drug exerts its 
therapeutic effect rarely gives any information of its kinetic parameters 
or of the ways the drug may affect the metabolism of another agent 
[8,9].
Metabolic pathways for psychoactive drugs
Metabolism can be an important determinant of the therapeutic 
activity, the interactions and the toxicity of psychoactive drugs. The 
common pattern of psychoactive drug metabolism is biphasic and 
consists of stepwise biotransformation and synthesis reactions. The 
major enzymatic reactions of drug metabolism are oxidation, reduction, 
and hydrolysis. These reactions are biotransformation reactions while 
conjugation is a synthesis reaction. A psychotropic drug may have a 
chemical structure suitable for biotransformation via one or more of 
these reactions.
Phase 1 (biotransformation) consists of the oxidation 
(hydroxylation), hydrolysis, or reduction of a lipid-soluble or nonpolar 
drug. The phase 1 enzymatic mechanisms most relevant to metabolism 
of psychoactive drugs are oxidation, reduction, and hydrolysis. CYP´s 
enzymes are responsible for most phase I reactions [6,17]. CYP´s will 
be described in more detail in the next section.
Phase 2 (synthesis) consists of the conjugation of a drug or its 
metabolite with an endogenous compound, mostly glycine, sulfate, 
or glucuronic acid. The result of either phase of metabolism is the 
production of metabolites that are generally more polar than the parent 
drug and are more readily excreted in the bile or urine. Both phases 
of biotransformation are the result of drug interaction with enzymes 
present in plasma, cytoplasm, mitochondria, and endoplasmic 
reticulum.
The most prominent phase 2 enzymatic family is the uridine 
5’-diphosphate glucuronosyl-transferases (UGTs). UGTs are identified 
by a nomenclature system (1A1, 1A4, 2B7, 2B15, etc.), and each 
enzyme has a unique range of substrates, inhibitors, and inducers. The 
metabolism of some psychoactive agents like olanzapine, lamotrigine, 
and certain narcotic agents, is performed primarily by the UGTs. Thus, 
an understanding of UGT metabolism is important to anticipate and 
prevent drug-drug interactions concerning these isozymes [3,18].
P-glycoprotein (P-gp) transporter is another important protein 
in metabolism of psychotropic drugs. P-gp is an ATP-dependent, 
extruding transporter. It resides in the plasma membrane of enterocytes 
of intestinal epithelium, and in this location regulates drug absorption. 
Like the P450 and UGT metabolic systems, the P-gp transporter has 
substrates, inhibitors, and inducers. P-gp is found in liver cells, in the 
cells of proximal renal tubules and in the capillaries of the blood-brain 
barrier, where it is one of the main elements that prevent substances 
entering to the CNS. Frequently, P-gp substrates, inhibitors and 
inducers have also involved with P450 system, and therefore it is not 
easy to discriminate the relative contribution of each metabolic system 
to a determined interaction or clinical effect [19,20].
The cytochrome P450 (CYP) system
It is necessary to take into account the cytochrome P450 system 
when pharmacokinetic interactions are considered. Cytochrome P450 
system is a superfamily of enzymes found mainly in the liver, are 
implicated in the metabolism of many drugs and have been shown 
to be involved in numerous interactions between drugs and foods, 
beverages, herbs and other medications [3,21].
Cytochrome P450 enzymes (CYP’s) are responsible for the oxidative 
metabolism of a wide variety of both exogenous and endogenous 
compounds. The CYP’s are a group of isoenzymes located primarily 
in the endoplasmic reticulum of hepatic cells. Drug metabolism by 
CYP’s takes place primarily in the liver, but CYP enzymes are also 
found in many other tissues, including central nervous system (CNS) 
[6,15,18,22].
CYP is an important superfamily of metabolizing enzymes, which 
are ubiquitously distributed in humans. The term ‘cytochrome P450’ 
was coined because of its spectral properties. In cytochrome P450, 
cytochrome stands for a hemoprotein, P for pigment and 450 reflects 
the absorption peak at 450 nm. Most of the CYP’s are found in the 
endoplasmic reticulum, and some are localized mainly in mitochondria. 
The CYP’s are involved in the metabolism of a broad variety of 
xenobiotics (drugs and chemical compounds which are foreign to 
the living organism) as well as endobiotics (endogenous compounds, 
including eicosanoids, cholesterol, hormones, and steroids) [23,24].
CYP genes have been described in 85 eukaryote (including 
vertebrates, invertebrates, fungi, and plants) and 20 prokaryote species. 
Of 74 gene families, 14 families exist in mammals. These 14 families 
comprise 26 mammalian subfamilies, of which more than 20 have 
been mapped in the human genome. Currently, in humans 57 different 
CYP genes (and more than 50 pseudogenes) are recognized, which are 
classified according to sequence homology into 18 families [23,25,26].
In 1966, Sladek and Mannering [27] demonstrated for the first time 
the presence of multiple forms of CYP´s in liver microsomes. Further 
studies showed that phenobarbital inducible isoforms were different 
from the other inducible isoenzymes of CYP. Additional purification 
and characterization studies in following years demonstrated that 
many different forms of CYP’s exist in the liver which has narrow 
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but overlapping substrate specificities [28,29]. Figure 1 shows the 
distribution of the major CYP drug-metabolizing enzymes in the 
human liver [30].
To bring uniformity to CYP´s classification, Nelson and colleagues 
proposed a nomenclature system in 1996 [26]. Based on amino acid 
sequence homologies, the CYP superfamily has been categorized into 
several families and subfamilies. Sequences that are 40% or more 
identical at the amino acid level belong to the same Family (designated 
by Arabic number). Sequences that are 60% or more identical belong 
to the same Subfamily, designated by a capital letter, and after this 
the individual genes are arbitrarily numbered (Table 1). It was 
recommended the root symbol ‘CYP’ for human, in contrast to ‘Cyp’ 
for mouse and Drosophila. Usually, the convention is to italicize the 
name when referring to the gene. For example, CYP2D6 is the gene that 
encodes the enzyme CYP2D6 [31].
In humans, the CYP superfamily is classified into 18 families and 
57 subfamilies. Members of families CYP1, CYP2 and CYP3 primarily 
metabolize xenobiotics, such as drugs and environmentally derived 
compounds, and certain endogenous substrates. The CYP2 family 
metabolizes a large proportion of CNS-acting psychopharmacological 
drugs, such as antidepressants and antipsychotics; drugs of abuse, such 
as amphetamine and ethanol; and some endogenous neurochemicals, 
such as dopamine and serotonin.
Polymorphisms and factors that influence CYP levels
The levels of CYP forms in plasma, brain, liver and other tissues 
vary widely among individuals. This can be caused by factors that affect 
CYP expression levels, including genetic polymorphisms, which can 
result in differences in the plasma levels of drugs and their metabolites. 
For example, there is substantial variation in the amount and function 
of CYP2D6 enzyme between individuals. CYP2D6 has the largest 
phenotypical variability among the CYP’s, mostly because of genetic 
polymorphism. The different alleles may show normal, reduced, and 
non-existent CYP2D6 function in different individuals [32,33].
Ethnic groups may show different patterns of CYP metabolization. 
For example, about 10% of white people have mutated alleles in their 
CYP2D6 that result in a functionally deficient CYP2D6 enzyme. 
These patients are known as poor metabolizers and often respond 
inadequately to psychotropic agents that are activated by CYP2D6. An 
ultrarapid metabolizer (1-3% of white population) is someone that has 
multiple copies of the CYP2D6 gene, and therefore greater CYP2D6 
function. Ultrarapid metabolizers may have very low plasma levels of 
certain drugs and treatment successful may be jeopardized in these 
patients. Extensive metabolizers have normal CYP2D6 function and 
metabolize drugs at a normal rate while intermediate metabolizers 
process drugs at a rate somewhere between the poor and extensive 
metabolizers.
Many CYP’s are sensitive to induction by xenobiotics (external 
chemical compounds, including drugs). For instance, metabolism of 
CYP1A2 is elevated in smokers. As a result, smokers may respond 
differently than nonsmokers to a psychoactive drug that is metabolized 
as a CYP1A2 substrate.
Age is another factor that can also influence CYP levels in liver, 
brain and other tissues. For example, the CYP2D6 in the brain is low 
at birth, increases gradually with age, and is highest in the elderly. In 
contrast, CYP2D6 hepatic level increases quickly after birth to adult 
levels and remains constant thereafter. This implies that for some CNS 
acting drugs, the elderly may respond differently than younger adults. 
These differences may contribute to the fact that individual elderly 
patients respond in a different way than younger patients to drugs that 
are inactivated by CYP2D6 like desipramine [3,32,33].
Antipsychotics and CYP isozymes
CYP-related drug interactions are usually derived from either 
enzyme inhibition or enzyme induction. CYP isozymes clinically 
relevant for antipsychotics are well characterized at the molecular level 
and their principal substrates have been recognized. Most of the main 
inhibitors and inducers have also been identified.
Inhibition of an enzyme typically implies competition with another 
drug for the enzyme binding site. Therefore, the rate of metabolism of 
a drug is reduced, which results in greater plasma levels and potentially 
leads to an augmentation of its pharmacologic effects. Many compounds 
may inhibit the activity of more than one CYP isozym [7,29,34,35].
Competitive inhibition is usually dose-dependent. Its effects may 
appear within hours of ingestion of the inhibitor, although the time to 
reach maximum inhibition depends on the respective plasma half-life 
of the drug and on the inhibitor. When the inhibitor is discontinued, 
return of previous conditions also depends on the time required to 
metabolize both the drug and the inhibiting agent.
Enzyme induction is a slow biologic process that is not only dose 
dependent but also time dependent. Enzyme induction may affect 
the pharmacokinetics of agents metabolized by the enzyme, as it can 
produce decreased plasma levels of a drug and therefore it can affect its 
clinical effectiveness. In general, the extent of induction is proportional 
to the dose of the inducing agent because the process requires synthesis 
of the new enzyme, but induction effects appear with a delay (in 
general, from 3 to 14 days) after exposure to the inducing agent. When 
the inducting agent is withdrawn, the time required for returning to 
baseline conditions depends on the rate of elimination of both the 
enzyme and the drug [3,35].
Many antipsychotics are metabolized by CYP isozymes. 
Understanding the metabolism of antipsychotics by the  CYP system 
can alert the clinician on how to avoid and manage drug-drug 
Figure 1: Distribution of the main CYP drug-metabolizing enzymes 
in the liver. CYP3A4 is the major form of CYP´s in the adult liver and 
metabolizes the greatest proportions of drugs. Although CYP2D6 represents 
approximately only 2% of the liver CYP content, it plays an important role in 
drug metabolism particularly in clinical psychopharmacology [30].
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interactions involving these enzymes. [6,7,29,34,35]. Table 2 shows the 
role of the most commonly used typical and atypical antipsychotics as 
substrates or inhibitors of main CYP enzymes [7,34,36,37].
The main CYP’s isozymes and its potential interactions with some 
commonly used antipsychotic agents are discussed in detail in the 
following section
3.5.1 CYP1A2: CYP1A2 constitutes about 13% of the total CYP 
content and is mainly a hepatic enzyme that metabolizes chemicals 
and environmental toxins. CYP1 family is mainly involved in the 
metabolism of polycyclic aromatic hydrocarbons and halogenated 
aromatic hydrocarbons. These CYP’s have substantial variations 
in activity due to a variety of modulating factors, such as genetic 
polymorphism, age, gender, disease status, pharmacotherapy, and 
dietary factors [38,39].
CYP1A2 has been shown to mainly catalyze the metabolism 
of polycyclic aromatic hydrocarbons (PAH), which are common 
components of cigarette smoke. CYP1A2 can activate benzopyrene, 
a carcinogen present in cigarette smoke, and it is a strong inducer of 
CYP1A2 since it can increase the synthesis of this isoenzyme by 3 fold. 
Other drugs metabolized by CYP1A2 include theophylline, warfarin, 
and several antidepressants and antipsychotics, including clozapine, 
haloperidol and olanzapine. Substrates and inhibitors for CYP1A2 
includes caffeine and cigarette smoke [40-43]. Table 3 shows the major 
substrates, inhibitors, and inducers of human CYP1A2 [7,17,34,39,41].
3.5. 2 CYP2D6: The CYP2 family is the largest and most diverse of 
the CYP families and is responsible for the metabolism of a wide variety 
of compounds. Although CYP2D6 only accounts for up to 2% of the 
liver CYP content [44,45], it has an important role in drug metabolism 
particularly for the clinical use in psychopharmacology. In humans, 
CYP2D6, is also expressed in various tissues including the kidney, 
placenta, brain, breast, lung and intestine [35,46,47].
CYP2D6 exhibit genetic polymorphism. CYP2D6 polymorphism 
has been the most studied human genetic polymorphism in drug 
metabolism with more than 80 identified alleles within the most 
diverse human population and ethnic groups. The activity of CYP2D6 
shows a bimodal distribution indicating the presence of dominant and 
recessive alleles in the population. It has been estimated that 7-10% of 
Caucasians are poor metabolizers [33,35,47,48].
At the moment, CYP2D6 is not inducible by pharmacological 
agents and therefore, CYP2D6 is generally regarded as non-inducible. 
Although quinidine is not a substrate for CYP2D6, it is a strong 
CYP2D6 inhibitor and therefore widely used in interactions studies 
[49]. CYP2D6 is the only CYP enzyme not inducible by other drugs. 
While some drugs such as rifampicin and dexamethasone were found 
to slightly induce CYP2D6 in humans, this effect is not considered 
clinically significant [17,50].
More than 80 drugs in clinical use are metabolized by CYP2D6 
and most of psychotropic agents are metabolized by this way. Since 
many antipsychotic are metabolized by CYP2D6, poor metabolizers 
The following is an example to illustrate the CYP naming system using CYP3A4:
The standard abbreviation for human cytochrome P450 is CYP.
Families of the isozyme which share greater than 40% protein sequence homology with each other are designated by the first number following the cytochrome P450 
designation, e.g., 3. 
Subfamilies which share greater than 60% homology with each other are differentiated by the letter following the family designation, e.g., A.
Single members of subfamilies represent a particular gene and are designated by the number following the subfamily description, e.g., 4. 
 Table 1: The cytochrome P450 nomenclature system [31].
Atypical CYP1A2 CYP2D6 CYP3A4
Amisulpride
Aripiprazole Substrate Substrate
Asenapine Substrate Inhibitor (weak)
Clotiapine








Typical CYP1A2 CYP2D6 CYP3A4
Chlorpromazine Substrate Inhibitor
Fluphenazine Substrate Inhibitor
Haloperidol Substrate Inhibitor (potent) Substrate
Levomepromazine Inhibitor
Perphenazine Inhibitor
Pimozide Substrate Inhibitor (potent) Substrate
Zuclopenthixol Substrate
Green color means that the drug is not metabolized by CYP-related metabolism or the metabolism is not significant clinically. Yellow means that the drug is a substrate of 
the isoenzyme and red is related to the inhibitory potential of the drug.
Data based on the respective drug labels and the following references: [7,34,36,37].
Table 2: Role of commonly used atypical and typical antipsychotics as substrates or inhibitors of major CYP isozymes.
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are at risk for ADR like postural hypotension and extrapyramidal side 
effects [33,47,48]. Table 4 shows the principal substrates, inhibitors, 
and inducers of human CYP1A2 [7,17,34,50].
3.5.3 CYP3A4: CYP3A4 accounts for approximately 30% of 
total hepatic content and 70% of CYP gut wall content. CYP3A4, is 
involved in metabolism of large number of endogenous and exogenous 
compounds. Since almost 50% of drugs are metabolized by CYP3A4, 
some of the most serious drug interactions have been caused by 
accumulation of substrates by the influence of inhibitors or inducers 
[21,51]. Strong inhibitors of CYP3A4 like erythromycin, ketoconazole, 
itraconazole and grape fruit juice have caused elevated substrate levels 
that have precipitated prolonged QT interval, torsades de pointes 
and even death [52]. Grape fruit juice may down-regulate CYP3A4 
expression in small intestine which can lead to a higher bioavailability 
of cyclosporine, terfenadine and triazolam [53,54]. Clarithromycin and 
erythromycin may decrease drugs metabolism by inhibiting CYP3A4. 
Rifampicin, carbamazepine, barbiturates and phenytoin are potent 
inducers of CYP3A4 [22].
Inhibitors and inducers of CYP3A4 may affect the metabolism of 
antipsychotics that are CYP3A4 substrates like quetiapine. Quetiapine 
pharmacokinetics is strongly affected by concomitant administration 
of clarithromycin, ketoconazole and carbamazepine. Other drugs that 
modulate the activity or expression of CYP3A4 would also affect the 
exposure to quetiapine [15]. CYP3A4 plays a major role of in hepatic 
bioactivation of clozapine, which cause hepatotoxicity in a small 
percentage of patients. Interindividual differences and drug-drug 
interactions at the level of CYP3A4 might cause changes in exposure of 
hepatic tissue to reactive clozapine metabolites [46].
CYP3A4 and P-glycoprotein (P-gp) may act together to limit 
oral drug bioavailability. CYP3A4 and P-gp are an integral part of an 
intestinal defense system to protect the body against xenobiotics. As 
a result, drugs that are substrates of both proteins often have a low 
bioavailability after oral administration. Both proteins are expressed in 
enterocytes and hepatocytes and contribute to a major extent to first-
pass elimination of many drugs. There is an overlapping of substrate 
specificities and inhibitor/inducers between CYP3A4 and P-gp. Many 
drug interactions may involve both CYP3A4 and P-gp and often 
it is difficult to discriminate the specific cause of drug interactions 
[19,55,56]. Table 5 shows the principal substrates, inhibitors, and 
inducers of human CYP3A4 [7,17,21,34].
Interactions with other substances
Sometimes the CYP´s inducers or inhibitors are commonly 
consumed substances such grape fruit juice, caffeine and tobacco 
smoke. In the case of grape fruit juice, there are many drugs known to 
interact including statins, antiarrhythmic agents, immunosuppressive 
agents, and calcium channel blockers. The inhibition of the enzyme 
system seems to be dose dependent; thus, the more a patient drinks 
grapefruit juice, the more the inhibition that occurs. In addition, the 
effects can last for several days if grapefruit juice is consumed on a 
regular basis. This effect has not been reported with other fruit juices 
[53,54].
Caffeine is a substrate of CYP1A2. When caffeine is ingested, there 
is less of CYP1A2 available to metabolize other drugs. Thus, caffeine 
acts as a metabolic inhibitor, slowing down the speed with which the 
organism can metabolize medications. The result is an increment of 
plasma level of these drugs, caffeine, or both. [39,41].
































































































Table 4: Main substrates and clinically relevant inhibitors, and inducers of human 
CYP2D6.
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Many psychiatric patients smoke, and are believed to be heavier 
smokers than those without psychiatric disorders. Cigarette smoking 
is one of the environmental factors that contribute to interindividual 
variations in response to an administered drug. It can affect drug 
therapy by both pharmacokinetic and pharmacodynamic mechanisms. 
Polycyclic aromatic hydrocarbons (PAH) in tobacco smoke are 
believed to be responsible for the induction of CYP1A1 and CYP1A2 
[16,40]. Clinicians must also be aware of the potential impact of 
stopping cigarette smoking on the metabolism of some psychoactive 
drugs, for example, clozapine and olanzapine [46]. Blood levels of these 
antipsychotics may be reduced as the hydrocarbons in cigarette smoke 
no longer induce the CYP system and blood levels of the affected drugs 
could increase to high levels. According to the last National Institute 
for Health and Care Excellence [43] Guideline on Psychosis and 
Schizophrenia in Adults, the effect of smoking on patients receiving 
clozapine is of particular concern and should be considered in advance 
of smoking cessation.
Polypharmacy
Drug-drug interactions constitute a main challenge in clinical 
practice, especially in elderly and other polymedicated patients. 
Polypharmacy has been associated with increased adverse drug 
reactions, hospitalization and mortality [57,58].
Loya et al. [32] conducted a study about prevalence of 
polypharmacy, use of herbal products, nutritional supplement and 
potential product interactions among older adults in the United States. 
In this descriptive study, 130 participants with a mean age of 71.4 years 
were recruited. The prevalence of polypharmacy among all participants 
was 72.3% (n=94). In addition, 21 participants (16.2%) reported that 
they were two or more herbal products (polyherbacy). Assessment of 
potential interactions showed that 46.2% (n=60) of participants were at 
risk of having at least one potential drug-drug interaction. Regarding 
drug and herbal product or supplement  interactions, 31.5% (n=41) 
of participants were at risk of having at least one possible interaction. 
According the authors, almost half of the older adults community-
dwelling were at risk for a potential drug-drug interaction, while 
approximately one-third were at risk for potential interaction between 
their prescription drugs, herbal products or nutraceutical supplements.
Even in an apparently healthy population, polypharmacy is an 
important concern for patient safety. Husson et al. [58] conducted a 
survey to assess the main characteristics associated with polypharmacy 
in 2,545 volunteers (1,175 women, and 1,370 men) aged 66 (± 4.8) years. 
In this study, polypharmacy was defined as the concomitant use of 4 or 
more drugs. Investigators found that the prevalence of polypharmacy 
was 29.9% in apparently healthy people aged 60 years and over.
A study of drug interactions among recently hospitalized patients 
(n=200) was conducted in Denmark, including, 83 surgical and 
117 medical patients. The median age of the population included 
was 75 years and 70% were women. In this survey, patients stored 
2119 medications at home (median: 9 per patient) and used 1622 
medications daily or on demand (median: 8 per patient). In total, 476 
potential interactions were identified in 126 patients (63% of patients), 
showing that there is a high potential of drug interactions, especially 
in elderly and other polymedicated patients [59]. In consequence, it is 
advisable that clinicians consider the risks associated to polypharmacy 
before issuing any prescriptions in elderly people to avoid drug-drug 
interactions. Usual strategies to avoid polypharmacy complications 
include dose adjustment or changing for another drug less or not 
susceptible to drug-drug interactions.
Clinical interactions in psychiatry
In psychiatry, the range of psychotropic agents has increased 
enormously over the last 2 decades and it implies that drug interactions 
have expanded as well [50,60]. In a recent retrospective review of 
hospitalized psychiatric patients, medication classes responsible for 
adverse drug reactions (ADRs) included mood stabilizers (30%), 
typical antipsychotics (25%), atypical antipsychotics (25%), and 
antidepressants (8%), and most of these ADRs were due to a drug-drug 
interaction [2].
The clinical effect a psychoactive drug has on a given patient may 
be different than expected because the drug interacts with another drug 
(drug-drug interaction) or with substances of common use, misuse 
or abuse (caffeine, nicotine, alcohol, and illegal substances). Food, 
beverages, vitamins, and supplements can also interact with drugs 
(food-drug or nutrient-drug interactions) [61-63].
Concomitant prescription of two or more antipsychotics is an 
increasingly common practice in psychiatry. This clinical practice 















































































Table 5: Main substrates and clinically relevant inhibitors, and inducers of human 
CYP3A4.
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antipsychotic monotherapy. A common reason for prescribing more 
than one antipsychotic is to gain a greater or more rapid therapeutic 
response than has been achieved with monotherapy. Surveys of 
prescribing in psychiatric centers have identified the relatively frequent 
and consistent use of combined antipsychotics, frequently for patients 
with schizophrenia, with a prevalence of around 50% in certain clinical 
settings [9,63,64].
The relatively widespread use of antipsychotic polypharmacy 
identified in clinical surveys reflects not only the addition of a second 
antipsychotic to improve therapeutic response, but also the use on 
demand of antipsychotic medication, especially to treat behavior 
disturbances. The evidence on the risks and benefits for such a strategy 
is not clear. Nevertheless, the most reasonable strategy seems to 
consider the pharmacodynamic and pharmacokinetic properties of the 
combined agents [63,65,66].
Potential interactions with antipsychotic agents
Clinical interactions are common with antipsychotic drugs. 
Most commonly used antipsychotic are metabolized through CYP´s 
hepatic pathways and this is the cause of frequent interactions. Some 
antipsychotic agents, like amilsupride and paliperidone, have a 
negligible hepatic biotransformation, and therefore are unlikely to be 
involved in clinically significant drug-drug interactions [67-70].
The metabolism and potential interactions of the main antipsychotic 
agents are discussed in detail in the following section [6,34,70].
Clozapine: Clozapine was the first second-generation antipsychotic 
released for clinical use. Therefore, there are more data available on 
its metabolism than on other medications in this class. Clozapine is 
primarily metabolized by CYP1A2 with many secondary pathways. It 
seems well established that CYP1A2 is involved in the metabolism of 
clozapine. Clozapine appears to be an in vitro P-glycoprotein substrate 
and it is also a mild inhibitor of 2D6. Clozapine has a low therapeutic 
index [38,46].
Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), 
inhibits CYP1A2, and can cause a strong inhibition of clozapine 
metabolism. Increased serum levels of clozapine after the start of 
fluvoxamine treatment have been reported from several cases [7,39].
There is evidence that interactions between clozapine and caffeine 
may be clinically relevant. It has been described that individuals 
being treated with clozapine showed signs of increased arousal and 
extrapyramidal symptoms after consuming caffeinated beverages. 
Usually, the signs and symptoms resolved when non-caffeinated drinks 
were substituted [39,41].
Cigarette smoking induces CYP1A2. Smokers have been observed 
to have lower serum levels of clozapine than nonsmokers, sometimes 
significantly lower. This interaction may be clinically relevant and 
must be take on account also when the patient is considering to stop 
smoking [40,42,43].
Risperidone: Compared to other commonly used antipsychotic 
agents, many publications have reported potential DDIs involving 
risperidone. Risperidone is mainly metabolized by through CYP2D6, 
and to a lesser extent by CYP 3A4. In vitro studies have shown that 
CYP2D6 catalyzes the metabolism of risperidone to its major active 
metabolite, 9-hydroxyrisperidone (paliperidone). Risperidone is also 
an in vitro P-glycoprotein substrate of moderate to strong affinity, and 
acts as a mild to moderate 2D6 inhibitor [3,6,34].
Olanzapine: The role of CYP’s in the metabolism of olanzapine 
has become clearer in recent years. Olanzapine is mostly metabolized 
by CYP1A2, with CYP2D6 and UGT serving as minor pathways. 
Olanzapine is also a P-glycoprotein substrate of low to moderate 
affinity and acts as a P-glycoprotein inhibitor.
CYP1A2 is responsible for the formation of N-desmethyl-
olanzapine and the formation of this metabolite correlated significantly 
with olanzapine clearance rates in vitro. Concomitant treatment with 
the CYP1A2 inhibitor fluvoxamine resulted in increased serum levels 
and decreased rates of clearance of olanzapine, along with decreased 
serum levels of N-desmethyl-olanzapine [7].
The polycyclic aromatic hydrocarbons contained in cigarette 
smoke are strong inducers of CYP1A2. Smokers have been observed 
to have changes in serum levels of olanzapine. This interaction may be 
clinically relevant [40,42,43].
Quetiapine: Quetiapine is primarily metabolized by CYP3A4. It 
is also a P-glycoprotein substrate of moderate to strong affinity and 
acts as a P-glycoprotein inhibitor. In a dosing study, concomitant 
administration of the CYP3A4 inhibitor ketoconazole resulted in 
a significant increase in serum quetiapine levels and its half-life. 
Concomitant administration of the CYP inducer phenytoin resulted 
in a significant decrease in serum quetiapine levels that corresponded 
with an increase in clearance rates. Since quetiapine is primarily 
metabolized by CYP3A4, the observed pharmacokinetic changes are 
due to induction of CYP3A [15,21,22,51].
Ziprasidone: Ziprasidone is principally metabolized by aldehyde 
oxidase, with CYP3A4 serving as a secondary pathway. In vitro data 
indicate that CYP3A4 is the primary CYP involved in the metabolism 
of ziprasidone. Concomitant administration of CYP3A4 inhibitors 
altered the drug’s pharmacokinetics. A significant increase in serum 
levels of ziprasidone was observed when the drug was administered 
along with ketoconazole [15,22,34].
Haloperidol: The metabolism of haloperidol is fairly complex. 
It is based mostly on CYP3A4 activity, with secondary contributions 
from 2D6 and 1A2, and other phase II reactions. Haloperidol 
appears to be a P-glycoprotein substrate of weak affinity. Some of 
haloperidol’s metabolites are also inhibitors of 2D6. Haloperidol is also 
a P-glycoprotein inhibitor. Haloperidol may increase anticholinergic 
and also may increase CNS depressant effects of anesthetics, opiates, 
and alcohol. A total of 972 drugs are known to interact with haloperidol 
[3,6,34].
Paliperidone: Paliperidone, or 9-hydroxy-risperidone, is the 
major active metabolite of risperidone. Due to its negligible hepatic 
biotransformation, paliperidone is unlikely to be involved in clinically 
significant metabolic interactions. In pharmacokinetic studies no 
metabolites could be detected in plasma. Renal excretion is the major 
route of elimination with 59% of the dose excreted unchanged in urine. 
Other four minor metabolic pathways were identified, each of which 
accounted for up to a maximum of 6.5% of the administered dose. 
There are additional properties in terms of its lower protein binding 
and decreased inhibition of P-glycoprotein that lead to a decreased 
potential for drug-drug interactions [67,68,70].
Aripiprazole: Metabolism of aripiprazole is approximately equally 
divided between CYP2D6 and CYP3A4. It doesn’t have any known 
inhibitory or inductive properties of clinical relevance [9,34].
Avoiding interactions with antipsychotic agents
In order to prevent drug interactions with antipsychotic agents 
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clinicians have to be particularly alert to drugs with a narrow 
therapeutic index or drugs that require a strictly stable serum 
concentrations such as anticoagulants, anticonvulsants, anti-infectives, 
cardiovascular therapeutics, oral contraceptives, glucocorticoids, 
immunosuppressants, sulphonylureas, theophyllines, antiretroviral 
agents  and other psychotropics. In addition, clinicians should 
remember some well-known inducers or inhibitors of CYP system, like 
rifampicin, ciprofloxacin, fluvoxamine, barbiturates, carbamazepine, 
phenytoin, and warfarin among others [6,34,64].
It is important for clinicians to stay alert when treating psychiatric 
patients with difficult comorbidities requiring polypharmacy, especially 
in elderly or in patients with reduced hepatic or renal function. 
Physicians must take into account that polypharmacy, comorbidity 
and the use of certain substances (grapefruit juice, caffeine, tobacco, 
alcohol) is the basic scenario for the development of clinically relevant 
interactions in a psychotic patient.
 The best approach to prevent clinical interactions is to be aware 
that they can occur. The choice of drugs with a pharmacokinetic 
profile with low potential for clinically relevant interactions is the most 
reasonable strategy for many psychiatric patients, especially for the 
elderly and polymedicated patients [4,57,68,71].
Conclusions
System may play a critical role in the magnitude and duration of the 
effects of drugs, either for their catabolic properties inactive metabolites 
or for the bioactivation of prodrugs to active drugs. These isoenzymes 
may also be involved in the development of reactive metabolites which 
can be allergenic, toxic or mutagenic.
The CYP´s isoenzymes are all inducible except CYP2D6. The genes 
encoding CYP2A6, CYP2C9, CYP2C19 and CYP2D6 are functionally 
polymorphic. In the case of CYP1A2 and CYP3A4, there are known 
polymorphisms, primarily in their regulatory regions, although its 
functional significance is not yet fully elucidated.
Drug-drug interactions are closely related to CYP system activity 
and are responsible for substantial patient morbidity. Drug-drug 
interactions are responsible for approximately 20% to 30% of adverse 
reactions. The risk for DDIs increases substantially when the number 
of concomitants drugs increase. Cigarette smoke, alcohol, caffeine and 
some nutrients are other factors that increase the risk of interactions. It 
must be highlighted that some food like cauliflower, broccoli or grilled 
meat, have the potential to be CYP450 inducers. As they can induce 
CYP1A2, they could interact with antipsychotics that are metabolized 
by the same isoenzyme, such as clozapine or olanzapine. These factors, 
added to a great variability of CYP system activity between individuals 
suggest that drug interactions are not always easy to recognize.
The knowledge of the metabolism of second generation 
antipsychotics by CYP´s can alert the physician about how to prevent 
and manage drug-drug interactions involving these enzymes.
Clozapine is metabolized primarily by CYP1A2, with additional 
contributions by CYP2C19, CYP2D6 and CYP3A4. Risperidone is 
metabolized primarily by CYP2D6 and to a lesser extent by CYP3A4. 
In contrast to the case of risperidone, the metabolism of paliperidone 
(9-hydroxy-risperidone) in the liver is very limited. Olanzapine is 
metabolized primarily by CYP1A2 and to a lesser extent by CYP2D6. 
Quetiapine and ziprasidone are metabolized by CYP3A4 [72].
The concomitant prescription of more than one antipsychotic is an 
increasingly common practice in clinical psychiatry. DDIs are some of 
the most common causes of morbidity related to the use of medication, 
particularly in aging patients due to polytherapy. For that reason, 
the choice of a drug with no or minimal potential of interactions is a 
reasonable approach in clinical psychiatry [73].
Since many antipsychotics are metabolized by CYP isozymes, there 
are some practical principles to prevent and resolve drug interactions. 
Clinicians must be alert to drugs with a low therapeutic index or that 
required a strictly stable serum concentration. Clinicians should also 
be vigilant when psychotropics are prescribed concurrently with other 
medications. Close monitoring of plasma drug levels should be carried 
out to assure efficacy and to avoid toxicity. In addition, they should 
remember the most well-known inducers or inhibitors of CYP system.
It is important for clinicians to be alert when treating psychiatric 
patients with difficult comorbidities requiring polypharmacy, especially 
in elderly or patients with reduced hepatic or renal function. Physicians 
must take into account that polypharmacy, comorbidity and the use of 
certain substances (grape fruit juice, caffeine, tobacco) improves the 
chances for clinically relevant interactions in a psychotic patient.
In summary, the choices of psychotropic drugs (for example, 
antipsychotics like paliperidone or amisulpride) that virtually do not 
interfere with the hepatic metabolism via the CYP´ssystem represent an 
alternative therapeutic approach for those patients with polypharmacy. 
Thus, the chance of having undesirable drug-drug interactions, mainly 
in those patients in whom it is essential to ensure stable therapeutic 
concentrations, are reduced, for example, in patients treated for 
substance abuse, cancer patients or HIV seropositive patients.
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